Year: 2023

CoreCard Corporation Reports Third Quarter 2023 Results

Written by Customer Service on November 1, 2023. Posted in Earnings Releases And Operating Results.

10% increase in Processing and Maintenance Revenue Year-over-Year NORCROSS, Ga., Nov. 01, 2023 (GLOBE NEWSWIRE) — CoreCard Corporation [NYSE: CCRD], the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, announced today its financial results for the quarter ended September 30, 2023. “Overall revenue of $13.4 million in the third quarter was in-line with our expectations, reflecting continued growth in processing and maintenance revenue of 10%, which was offset by lower professional services revenue, primarily driven by our largest customer. We continue to invest in our platform and processing capabilities, which are showing encouraging results. CoreCard provides a best-in-class credit platform that is extremely well positioned to capture the...

DT Midstream Reports Strong Third Quarter 2023 Results

Written by Customer Service on November 1, 2023. Posted in Earnings Releases And Operating Results.

Updates 2023 Adjusted EBITDA guidance to $905 to $925 million Updates 2023 Distributable Cash Flow guidance to $650 to $675 million Announces dividend of $0.69 per shareDETROIT, Nov. 01, 2023 (GLOBE NEWSWIRE) — DT Midstream, Inc. (NYSE: DTM) today announced third quarter 2023 reported net income of $91 million, or $0.94 per diluted share. For the third quarter of 2023, operating earnings were $91 million, or $0.94 per diluted share. Adjusted EBITDA for the quarter was $236 million. Reconciliations of operating earnings and adjusted EBITDA (non-GAAP measures) to reported net income are included at the end of this news release. The company also announced that the DT Midstream Board of Directors declared a $0.69 per share dividend on its common stock payable January 15, 2024 to stockholders of record at the close of business December...

InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update

Written by Customer Service on November 1, 2023. Posted in Earnings Releases And Operating Results.

Single ascending dose (SAD) Phase I data confirm best-in-class potential of orally available C5aR inhibitor INF904; multiple ascending dose (MAD) part ongoing Six clinical sites initiated; first patients screened in Phase III trial of vilobelimab in pyoderma gangrenosum (PG) FDA regulatory pathway towards BLA in broader acute respiratory distress syndrome (ARDS) indication discussed in encouraging FDA Type C meeting MAA for vilobelimab for treatment of SARS-CoV-2 induced septic ARDS in critically ill COVID-19 patients submitted and validated by EMA Update on development of vilobelimab in cutaneous squamous cell carcinoma (cSCC) First commercial sales for Gohibic (vilobelimab) recorded in the third quarter 2023 Cash, cash equivalents and marketable securities of €113 million, expected to fund operations at least into 2026JENA, Germany,...

trivago Announces Ex-Dividend Date for Extraordinary Dividend and Updates Effective Date for the Ratio Change under its American Depositary Share Program

Written by Customer Service on November 1, 2023. Posted in Dividend Reports And Estimates.

DÜSSELDORF, Germany, November 1, 2023 – trivago N.V. (NASDAQ: TRVG) announced today that, in connection with the Company’s recently announced one-time extraordinary cash dividend of EUR 0.529228 per share (the “Extraordinary Dividend”), Nasdaq has determined that the ex-dividend date for the Extraordinary Dividend will be November 14, 2023 (the “Ex-Dividend Date”). The payment of the distribution on the Company’s American Depositary Shares (“ADSs”) remains anticipated to be made on November 13, 2023, as previously announced by the Company. Since the payment of the Extraordinary Dividend represents more than 25% of the price of the Company’s ADSs, Nasdaq has determined that the Company’s ADSs will trade with “due bills” representing an assignment of the right to receive the Extraordinary Dividend from the record date of November...

Avista Corp. Reports Financial Results for the Third Quarter of 2023

Written by Customer Service on November 1, 2023. Posted in Earnings Releases And Operating Results.

SPOKANE, Wash., Nov. 01, 2023 (GLOBE NEWSWIRE) — Avista Corp. (NYSE: AVA) today reported net income of $14.7 million, or earnings of $0.19 per diluted share, for the third quarter of 2023, compared to a net loss of $5.8 million, or $0.08 per diluted share, for the third quarter of 2022. For the nine months ended Sept. 30, 2023, net income was $87.0 million, or $1.14 per diluted share, compared to $77.2 million, or $1.06 per diluted share for the nine months ended Sept. 30, 2022. “Avista Utilities’ results for the third quarter are ahead of our expectations. Our results reflect the steps we’ve taken this year to execute our strategy, including constructive regulatory outcomes and our ongoing diligence in managing costs. So much hard work has gone into our execution, work that will continue into 2024 as we file our next...

Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results

Written by Customer Service on November 1, 2023. Posted in Earnings Releases And Operating Results.

Generated total revenues of $110.4 million in the third quarter, including $75.3 million for SYFOVRE® (pegcetacoplan injection) and $23.9 million for EMPAVELI® (pegcetacoplan) SYFOVRE showed continued strong demand with growth week-over-week starting in August; permanent J-code effective as of October 1 Completed corporate restructuring aimed at driving growth of SYFOVRE and EMPAVELI and strengthening operational efficiencies Positive top-line data from Phase 2 NOBLE study investigating pegcetacoplan in post-transplant recurrence of primary IC-MPGN and C3G to be presented at Kidney Week Cash and cash equivalents of $452 million as of September 30, 2023; expected cash runway into at least 2Q 2025WALTHAM, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced its third quarter 2023...

G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights

Written by Customer Service on November 1, 2023. Posted in Earnings Releases And Operating Results.

– Recognized Total Revenue of $12.3 Million, Including $10.8 Million in Net COSELA® (trilaciclib) Revenue; Vial Volume Grew 3% Over Prior Quarter – – Confirmed Expectation of Interim Overall Survival (OS) Analysis for Pivotal Phase 3 PRESERVE 2 Trial in Metastatic Triple Negative Breast Cancer (TNBC) in the First Quarter of 2024 – – Reiterated Expectation of Initial OS Results from Phase 2 Trial of Trilaciclib in Combination with an Antibody-Drug Conjugate (ADC) in the First Quarter of 2024 – – COSELA Recommended in Updated American Society of Clinical Oncology (ASCO) Small Cell Lung Cancer (SCLC) Guidelines – – Management to Host Webcast and Conference Call today at 8:30 AM ET – RESEARCH TRIANGLE PARK, N.C., Nov. 01, 2023 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq:...

Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Written by Customer Service on November 1, 2023. Posted in Earnings Releases And Operating Results.

Raised $499 million of net proceeds from public offering of common stock, expected to support operations into 2026 2024 data readout timelines for emraclidine, darigabat, and tavapadon remain on track Tavapadon investor webcast scheduled for December 11, 2023 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) — Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the third quarter ended September 30, 2023 and provided key pipeline and business updates. “Cerevel is bringing forward one of the broadest neuroscience pipelines in the industry, with novel approaches to treating challenging diseases, and we remain focused on execution as we head into multiple data readouts in 2024,” said...

Apollo Reports Third Quarter 2023 Results

Written by Customer Service on November 1, 2023. Posted in Dividend Reports And Estimates.

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) — Apollo Global Management, Inc. (NYSE: APO) (together with its consolidated subsidiaries, “Apollo”) today reported results for the third quarter ended September 30, 2023. Marc Rowan, Chief Executive Officer at Apollo said, “Amid challenging market conditions for many, the resilience and growth characteristics of our differentiated business model are evident. The combined strength of our leading Asset Management and Retirement Services franchises positions us well to benefit in the current environment while providing unparalleled alignment with our clients. These are the periods in which we excel, and we’re on track to complete a strong year of execution.” Apollo issued a full detailed presentation of its third quarter ended September 30, 2023 results, which can be viewed on Apollo’s Investor...

Sprott Announces Third Quarter 2023 Results

Written by Customer Service on November 1, 2023. Posted in Public Companies.

TORONTO, Nov. 01, 2023 (GLOBE NEWSWIRE) — Sprott Inc. (NYSE/TSX: SII) (“Sprott” or the “Company”) today announced its financial results for the three and nine months ended September 30, 2023. Management commentary “Despite another challenging period for investors in all asset categories, Sprott continues to deliver positive net sales and asset growth, finishing September with $25.4 billion in Assets Under Management (“AUM”),” said Whitney George, Chief Executive Officer of Sprott. “Our expansion into energy transition investments is paying off, driven largely by the success of our uranium strategies. Since entering this area in mid-2021, our uranium strategies have grown to $6.3 billion in AUM and energy transition investments now make up approximately 25% of our consolidated AUM. During the third...

Year: 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals